http://www.usamci.com text only  

University of South Alabama

Page Content   Main Links

Contact Us   Links   Map & Driving Directions   Home   USA College of Medicine   USA Home
Seema Singh, Ph.D.

Instructor of Oncologic Sciences

Office:
USA Mitchell Cancer Institute
1660 Springhill Avenue
Mobile, AL. 36604
(251) 445-9844
(251) 460-6994 fax
seemasingh@usouthal.edu

Research Interests:
-Chemokine signaling in cancer progression, angiogenesis and metastasis.
-Cancer stem cells

Honors and Academic Achievements:
-First ranking in M.S. (Pathology and Microbiology), Aligarh M. University, Aligarh, India, (1994)
-Junior/Senior Research Fellowships, Central Inst. Med. Aromat. Pl. (CIMAP), Lucknow, India (1996-2001)
-Second place in Science debate, Central Inst. Med. Aromat. Pl. (CIMAP), Lucknow, India, (1997)
-Paper published in British Journal of Cancer selected for press release by Cancer Research, U.K., (2009)

Education:
-Ph.D., Aligarh M. University, India, Botany, Pathology & Microbiology, (2001)
-M.S., Aligarh M. University, India, Botany, Pathology and Microbiology, (1994)
-B.S., Aligarh M. University, India, Botany, Chemistry, Zoology, (1992)

Professional Appointments:
-Member, USA Mitchell Cancer Institute, 2009-present

Chemokines are a large group of low molecular weight cytokines, whose primary function is to serve as leukocyte attractants. However, recent evidence indicates that chemokines also play a role in a number of tumor-related processes [Cancer Meta. Rev. 26(3-4):453-67, 2007]. Chemokines bind to G-coupled, seven trans-membrane spanning cell-surface receptors (GPCR) to activate downstream cell signaling. Importantly, several recent studies have also identified chemokines as markers for “cancer stem cells” [Clin Exp Metastasis. 25(1):11-32, 2008; Cancer Res. 69(4):1302-13, 2009]. Our work has demonstrated multiple pathological implications of two chemokine receptors, CXCR1 and CXCR2, in melanoma growth, angiogenesis and metastasis [Brit. J. Cancer. 100(10):1638-46, 2009]. We have shown that targeting CXCR1/2 using small molecule inhibitors can repress melanoma growth and progression indicating a potential therapeutic benefit [Clin. Cancer Res. 15(7):2380-6, 2009]. Our laboratory is currently focused on identifying the precise downstream signaling elicited by CXCR1/2 upon CXCL8 ligand binding, defining cross-talk with other cell signaling pathways, and investigating the pathological significance of CXCR1/2 and other chemokine receptors in gynecological malignancies.

1. Singh S., Sadanandam, A., and Singh, R.K. (2007). Chemokines in tumor angiogenesis and metastasis. Cancer Meta. Rev. 26(3-4): 453-467.

2. Singh, S., Varney, M.L., and Singh, R.K. (2009). Host CXCR2-dependent regulation of melanoma growth, angiogenesis and experimental lung metastasis. Cancer Res. 69(2): 411-415.

3. Singh, S., Sadanandam, A., Varney, M.L., Mayer-Ezel, R., Bond, R. and Singh, R.K. (2009). Small molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival and angiogenesis. Clin. Cancer Res. 15(7): 2380-2386.

4. Singh, S., Nannuru, K., Sadanandam, A., Varney, M.L., and Singh, R.K. (2009). CXCR1 and CXCR2 enhance human melanoma tumorigenesis, growth and invasion. Brit. J. Cancer 100(10):.1638-1646.

5. Singh, S., Zahid, M., Saeed, M., Gaikwad, N.W., Meza, J.L., Cavalieri, E.L., Rogan, E.G., and Chakravarti, D. (2009). NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells. J Steroid Biochem Mol Biol. Jul 20. (In press).

-U.S. Patent # 20020076802 (2000). Novel streptomyces strain with potential antimicrobial activity against phyto-pathogenic fungi.

Top of page

---

Usablenet Assistive is a UsableNet product. Usablenet Assistive Main Page.